Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Drug Profile

JTV 519

Alternative Names: JTV-519; K201 - Merck; K201 - Sequel

Latest Information Update: 21 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aetas Pharma; Japan Tobacco
  • Developer Aetas Pharma; Sequel Pharmaceuticals
  • Class Small molecules; Thiazepines
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heart failure
  • Research Arrhythmias; Diabetes mellitus; Kidney disorders
  • Discontinued Atrial fibrillation; Cancer; Myocardial infarction

Most Recent Events

  • 21 Oct 2024 JTV 519 is still in preclinical development for Heart failure in Japan (IV) (Aetas Pharma Pipeline, October 2024)
  • 21 Oct 2024 Early research in Arrhythmias in Japan (unspecified route) prior to October 2024 (Aetas Pharma Pipeline, October 2024)
  • 21 Oct 2024 Early research in Diabetes mellitus in Japan (unspecified route) prior to October 2024 (Aetas Pharma Pipeline, October 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days